Nexalin Technology Inc. (NXL)
| Bid | 2.15 |
| Market Cap | 28.2M |
| Revenue (ttm) | 261.18K |
| Net Income (ttm) | -11.78M |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -2.55 |
| Forward PE | -5.98 |
| Analyst | Buy |
| Ask | 2.25 |
| Volume | 115,756 |
| Avg. Volume (20D) | 302,610 |
| Open | 2.38 |
| Previous Close | 2.34 |
| Day's Range | 2.12 - 2.39 |
| 52-Week Range | 0.50 - 4.49 |
| Beta | 4.39 |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various m...
Analyst Forecast
According to 1 analyst ratings, the average rating for NXL stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 135.85% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
11 months ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
